Diagnostic Value of miR-103 in Patients with Sepsis and Noninfectious SIRS and Its Regulatory Role in LPS-Induced Inflammatory Response by Targeting TLR4

Abstract

Background. Sepsis is a life-threatening condition and a systemic inflammatory response syndrome (SIRS) driven by infection. This study aimed at investigating the expression of microRNA-103 (miR-103) in sepsis patients, evaluating its diagnostic value, and exploring the regulatory effect of miR-103 on LPS-induced inflammation in monocytes. Methods. Expression of miR-103 was measured using quantitative real-time PCR. A receiver operating characteristics curve was plotted to evaluate the diagnostic vale of miR-103. Serum and cell supernatant levels of proinflammatory cytokines were analyzed using ELISA. The interaction between miR-103 and Toll-like receptors 4 (TLR4) was analyzed using luciferase reporter assay. The effect of miR-103 on inflammation was examined in LPS-treated monocytes. Results. Serum expression of miR-103 was decreased in noninfectious SIRS and sepsis patients compared with healthy controls, and the lowest expression value was observed in sepsis patients (all P<0.05). Serum levels of miR-103 have considerable diagnostic accuracy in distinguishing sepsis patients from SIRS patients and healthy controls. A negative correlation was found between miR-103 and inflammatory responses in sepsis patients. TLR4 was demonstrated to be a direct target of miR-103 and was negatively regulated by miR-103 in monocytes. The promoted inflammatory responses by LPS in monocytes were reversed by the overexpression of miR-103. Conclusion. All the data revealed that serum decreased miR-103 in sepsis patients serves as a promising noninvasive diagnostic biomarker and may be involved in the pathogenesis of sepsis by regulating inflammatory responses via targeting TLR4.

MicroRNA‑1323 serves as a biomarker in gestational diabetes mellitus and aggravates high glucose‑induced inhibition of trophoblast cell viability by suppressing TP53INP1

“…miRNAs have been considered as ideal diagnostic tools for various human diseases due to their abnormal expression and stability in blood samples ( 27 ). For example, decreased levels of serum miR-103 may be used as non-invasive diagnostic biomarkers in patients with sepsis ( 28 ) and decreased levels of serum miR-375 may serve as biomarkers for the diagnosis of osteosarcoma ( 29 ). Considering the increased expression of miR-1323 in patients with GDM, ROC curves were plotted based on the miR-1323 expression and revealed that miR-1323 may be a potential diagnostic biomarker for patients with GDM.…”

Cellular microRNAs correlate with clinical parameters in multiple injury patients

“…Prior studies in sepsis have demonstrated similar findings with lower levels of microRNAs (miR-23a-5p, miR-26a-5p, miR-26b-5p, miR-103a-3p, miR-150-5p) in septic patients compared with healthy controls; however, systemic levels of these cellular microRNAs were increased in patients with severe sepsis or sepsis mortality. 16,20,37,41,42 Given the concurrent findings between PtPs in our study and sepsis studies, these microRNAs may yield early predictive value for trauma patients at risk for infectious complications and poor outcomes in trauma. Further evaluation of miR-103a-3p as a marker of VTE is merited given that the association between elevated levels of miR-103a-3p and VTE has been previously described in patients with recurrent VTE and potential mechanisms of action have been proposed.…”

Changes in miroRNA‐103 expression in wound margin tissue are related to wound healing of diabetes foot ulcers

“…The Wagner classification of the DFUs selected in this study was class II‐III, with mild to moderate infection status. Previous research has found that serum miR‐103 expression is reduced in patients with non‐infectious systemic inflammatory response syndrome and sepsis compared with healthy controls 40 . However, some studies have shown that the expression level of miR‐103 is increased in the peripheral blood of patients with type 2 diabetes 36,37 .…”

“…Previous research has found that serum miR‐103 expression is reduced in patients with non‐infectious systemic inflammatory response syndrome and sepsis compared with healthy controls. 40 However, some studies have shown that the expression level of miR‐103 is increased in the peripheral blood of patients with type 2 diabetes. 36 , 37 These results suggest that hyperglycemia and inflammatory responses may mutually inversely regulate the expression of miR‐103 in peripheral blood.…”